Nureca Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Revenue from branded healthcare products: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Promoters have been increasing their shareholding - up 4.9pp over 2 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 7.64x)
- Operating margins have improved to -1.6% from -7.0%
- Working capital cycle has improved - days down from 500 to 219
- Company generates healthy free cash flow
CONS
- Company is loss-making at the operating / net level
- A large part of profit comes from other income (293.4% of PBT)
- Receivables are growing faster than sales - a possible quality concern
- Recent results are weak - TTM profit is down 61.5% versus prior year
- Company has a low return on capital employed of 0.3%
- Company has a low return on equity of -0.5% over last 3 years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LENSKART | 694.05 | 184.20 | 120716.54 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| POLYMED | 1723.80 | 55.45 | 17472.69 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| MOLBIO | 1258.10 | 87.03 | 14498.34 | 0.00 | 527.44 | — | 4083.76 | — | 19.79 | 24.63 |
| 3BBLACKBIO | 1472.10 | 22.75 | 1263.45 | 0.34 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| LAXMIDENTL | 200.40 | 35.70 | 1102.79 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| NURECA | 332.45 | 73.14 | 317.22 | 0.00 | 3.07 | 277.24 | 40.34 | 18.03 | 3.31 | 8.48 |
| GKB | 66.13 | 10.28 | 33.33 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 31 | 22 | 20 | 23 | 32 | 27 | 32 | 34 | 38 | 40 | 35 | 40 | |
| 24 | 30 | 27 | 24 | 26 | 35 | 32 | 31 | 35 | 35 | 37 | 42 | 39 | |
| Operating Profit | -3 | 1 | -4 | -5 | -3 | -3 | -5 | 1 | -1 | 3 | 2 | -7 | 2 |
| OPM % | -14.08% | 3.32% | -19.80% | -24.34% | -12.53% | -8.22% | -17.38% | 1.80% | -3.15% | 6.92% | 6.03% | -18.47% | 4.21% |
| 3 | 3 | 6 | -1 | 6 | 3 | 2 | 2 | 3 | 2 | 2 | 1 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit before Tax | -1 | 4 | 1 | -7 | 2 | -0 | -4 | 2 | 1 | 4 | 4 | -6 | 4 |
| Tax % | 22.92% | 26.87% | 90.36% | 34.57% | 44.91% | -140.74% | 14.55% | -38.00% | 33.73% | 23.60% | 20.25% | -7.64% | 32.80% |
| Net Profit | -1 | 3 | 0 | -4 | 1 | -1 | -3 | 2 | 1 | 3 | 3 | -7 | 2 |
| -0.74 | 2.64 | 0.08 | -4.41 | 1.19 | -0.65 | -3.29 | 2.07 | 0.55 | 3.14 | 3.39 | -6.95 | 2.55 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 147 | 153 | |
| 1 | 1 | 90 | 152 | 200 | 127 | 106 | 125 | 150 | 153 | |
| Operating Profit | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | -3 | 0 |
| OPM % | 4.04% | 4.24% | 9.76% | 28.91% | 21.82% | -13.75% | -11.80% | -8.72% | -1.77% | 0.11% |
| 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | 8 | |
| Interest | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before Tax | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 3 | 6 |
| Tax % | 25.75% | 27.61% | 25.66% | 25.54% | 26.12% | 23.14% | 25.30% | -45.22% | 89.53% | 61.24% |
| Net Profit | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 0 | 2 |
| EPS | 15.64 | 20.75 | 9.16 | 62.25 | 45.31 | -8.42 | -2.44 | -0.67 | 0.31 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 4.30% | 6.62% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- -7%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -64%
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- -27%
- 3 Years:
- -3%
- 1 Year:
- 35%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 4%
- 3 Years:
- 0%
- Last Year:
- 0%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 10 | 10 | 10 | 10 | 10 | 10 |
| 0 | 14 | 153 | 194 | 185 | 183 | 182 | 168 | |
| 0 | 9 | 3 | 3 | 2 | 2 | 3 | 1 | |
| Trade Payables | 1 | 6 | 9 | 5 | 5 | 5 | 6 | 6 |
| 0 | 5 | 25 | 41 | 2 | 0 | 2 | 8 | |
| Total Liabilities | 1 | 34 | 200 | 252 | 204 | 200 | 203 | 192 |
| 0 | 1 | 3 | 10 | 8 | 6 | 8 | 12 | |
| 0 | 0 | 1 | 34 | 62 | 97 | 4 | 4 | |
| 1 | 16 | 37 | 63 | 33 | 29 | 36 | 45 | |
| 0 | 0 | 0 | 0 | 0 | 2 | 5 | 10 | |
| Cash & Bank | 0 | 0 | 126 | 84 | 71 | 45 | 127 | 41 |
| 0 | 16 | 33 | 61 | 30 | 21 | 24 | 79 | |
| Total Assets | 1 | 34 | 200 | 252 | 204 | 200 | 203 | 192 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -8 | 50 | 20 | 16 | -3 | -19 | 0 | |
| Cash from Investing | 0 | -0 | -0 | -110 | -3 | -18 | 18 | 9 | 16 |
| Cash from Financing | 0 | 0 | 8 | 92 | -7 | -2 | -1 | -1 | -19 |
| 0 | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-10 - Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations)'.
2026-09-09 - Nureca Limited has informed the Exchange regarding ''Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations)''.
2026-08-29 - Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'.
2026-08-21 - Nureca Limited has informed the Exchange about Action(s) taken or orders passed
2026-08-11 - Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).'.
2026-08-07 - Nureca Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-07-28 - Nureca Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results.
2026-07-28 - Nureca Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2026
2026-07-22 - Nureca Limited has informed the Exchange about Copy of Newspaper Publication
News
Recent coverage and analyst commentary for NURECA
Loading news…
AI Stock Analyst
Nureca Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account